164 related articles for article (PubMed ID: 20559008)
1. Pimecrolimus induces apoptosis of mast cells in a murine model of cutaneous mastocytosis.
Ma Z; Tovar JP; Kwong KY; Paek D
Int Arch Allergy Immunol; 2010; 153(4):413-8. PubMed ID: 20559008
[TBL] [Abstract][Full Text] [Related]
2. Topical pimecrolimus and tacrolimus transiently induce neuropeptide release and mast cell degranulation in murine skin.
Ständer S; Ständer H; Seeliger S; Luger TA; Steinhoff M
Br J Dermatol; 2007 May; 156(5):1020-6. PubMed ID: 17388925
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous mastocytosis: Two pediatric cases treated with topical pimecrolimus.
Correia O; Duarte AF; Quirino P; Azevedo R; Delgado L
Dermatol Online J; 2010 May; 16(5):8. PubMed ID: 20492825
[TBL] [Abstract][Full Text] [Related]
4. Mast cells as targets of pimecrolimus.
Ma Z; Jiao Z
Curr Pharm Des; 2011 Nov; 17(34):3823-9. PubMed ID: 22114844
[TBL] [Abstract][Full Text] [Related]
5. Effects of topical treatment with the raft modulator miltefosine and clobetasol in cutaneous mastocytosis: a randomized, double-blind, placebo-controlled trial.
Hartmann K; Siebenhaar F; Belloni B; Brockow K; Eben R; Hartmann B; Ruëff F; Schoepke N; Staubach P; Weber A; Maurer M
Br J Dermatol; 2010 Jan; 162(1):185-90. PubMed ID: 19785605
[TBL] [Abstract][Full Text] [Related]
6. Ablation of human skin mast cells in situ by lysosomotropic agents.
Hagforsen E; Paivandy A; Lampinen M; Weström S; Calounova G; Melo FR; Rollman O; Pejler G
Exp Dermatol; 2015 Jul; 24(7):516-21. PubMed ID: 25808581
[TBL] [Abstract][Full Text] [Related]
7. The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils.
Zuberbier T; Chong SU; Grunow K; Guhl S; Welker P; Grassberger M; Henz BM
J Allergy Clin Immunol; 2001 Aug; 108(2):275-80. PubMed ID: 11496246
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous mastocytosis in a patient with primary Sjögren's syndrome.
Kalay Erbay S; Stewart C; Hassanein A; Fletcher A; Bhattacharyya I; Cohen D; Wesson SK; Weinstein J; Lyons R; Reeves WH
J Rheumatol; 2006 Aug; 33(8):1697-700. PubMed ID: 16881127
[TBL] [Abstract][Full Text] [Related]
9. Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis.
Hoetzenecker W; Ecker R; Kopp T; Stuetz A; Stingl G; Elbe-Bürger A
J Allergy Clin Immunol; 2005 Jun; 115(6):1276-83. PubMed ID: 15940147
[TBL] [Abstract][Full Text] [Related]
10. Pimecrolimus -- an anti-inflammatory drug targeting the skin.
Grassberger M; Steinhoff M; Schneider D; Luger TA
Exp Dermatol; 2004 Dec; 13(12):721-30. PubMed ID: 15560755
[TBL] [Abstract][Full Text] [Related]
11. [Cutaneous mastocytosis].
Flageul B
Rev Prat; 2006 Oct; 56(16):1745-51. PubMed ID: 17315498
[TBL] [Abstract][Full Text] [Related]
12. Topical pimecrolimus and tacrolimus do not accelerate photocarcinogenesis in hairless mice after UVA or simulated solar radiation.
Lerche CM; Philipsen PA; Poulsen T; Wulf HC
Exp Dermatol; 2009 Mar; 18(3):246-51. PubMed ID: 19183401
[TBL] [Abstract][Full Text] [Related]
13. Topical tacrolimus and pimecrolimus: future directions.
Ling MR
Semin Cutan Med Surg; 2001 Dec; 20(4):268-74. PubMed ID: 11770914
[TBL] [Abstract][Full Text] [Related]
14. Pimecrolimus (Elidel, SDZ ASM 981)--preclinical pharmacologic profile and skin selectivity.
Stuetz A; Grassberger M; Meingassner JG
Semin Cutan Med Surg; 2001 Dec; 20(4):233-41. PubMed ID: 11770910
[TBL] [Abstract][Full Text] [Related]
15. An exploratory study to evaluate the efficacy of pimecrolimus cream 1% for the treatment of pityriasis alba.
Fujita WH; McCormick CL; Parneix-Spake A
Int J Dermatol; 2007 Jul; 46(7):700-5. PubMed ID: 17614797
[TBL] [Abstract][Full Text] [Related]
16. Mastocytosis: state of the art.
Horny HP; Sotlar K; Valent P
Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
[TBL] [Abstract][Full Text] [Related]
17. The BH3-mimetic ABT-737 induces mast cell apoptosis in vitro and in vivo: potential for therapeutics.
Karlberg M; Ekoff M; Huang DC; Mustonen P; Harvima IT; Nilsson G
J Immunol; 2010 Aug; 185(4):2555-62. PubMed ID: 20639495
[TBL] [Abstract][Full Text] [Related]
18. Pseudoxanthomatous mastocytosis.
Srivastava N; Chand S; Singh S
Int J Dermatol; 2008 Jan; 47(1):50-1. PubMed ID: 18173602
[No Abstract] [Full Text] [Related]
19. Pimecrolimus cream 1%: a new development in nonsteroid topical treatment of inflammatory skin diseases.
Hebert AA; Warken KA; Cherill R
Semin Cutan Med Surg; 2001 Dec; 20(4):260-7. PubMed ID: 11770913
[TBL] [Abstract][Full Text] [Related]
20. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study.
Gribetz C; Ling M; Lebwohl M; Pariser D; Draelos Z; Gottlieb AB; Zaias N; Chen DM; Parneix-Spake A; Hultsch T; Menter A
J Am Acad Dermatol; 2004 Nov; 51(5):731-8. PubMed ID: 15523351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
